Nordic Nanovector ASA (OSE: NANO) – MANDATORY NOTIFICATION OF TRADE

Oslo, Norway 27 October 2015:

Jostein Dahle, who is the Chief Scientific Officer of Nordic Nanovector ASA, purchased yesterday 3,800 shares in Nordic Nanovector ASA at an average share price of NOK 13.16 per share.

Following the transaction, Jostein Dahle and his close associate hold 254,958 shares in Nordic Nanovector ASA. Jostein Dahle holds 125,000 share options in Nordic Nanovector ASA.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe